Passage Bio Revenue and Competitors
Estimated Revenue & Valuation
- Passage Bio's estimated annual revenue is currently $25.9M per year.
- Passage Bio's estimated revenue per employee is $281,359
- Passage Bio's total funding is $379.5M.
- Passage Bio's current valuation is $311.1M. (January 2022)
Employee Data
- Passage Bio has 92 Employees.
- Passage Bio grew their employee count by -30% last year.
Passage Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Assistant to the CEO and Manager, Corporate Operations | Reveal Email/Phone |
2 | VP Manufacturing Operations | Reveal Email/Phone |
3 | VP, Clinical Development | Reveal Email/Phone |
4 | SVP Corporate Development & Investor Relations | Reveal Email/Phone |
5 | VP | Reveal Email/Phone |
6 | VP Pharmaceutical Supply Chain | Reveal Email/Phone |
7 | Head Regulatory CMC | Reveal Email/Phone |
8 | Executive Director Analytical Development & Quality Control | Reveal Email/Phone |
9 | Sr. Director, Market Research & Competitive Intelligence | Reveal Email/Phone |
10 | SVP Finance, Interim Chief Financial Officer | Reveal Email/Phone |
Passage Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 7 | -12% | N/A | N/A |
#2 | $4M | 38 | 81% | N/A | N/A |
#3 | N/A | 76 | 27% | N/A | N/A |
#4 | $0.9M | 5 | 0% | N/A | N/A |
#5 | $1.1M | 8 | 33% | N/A | N/A |
#6 | $10.9M | 61 | 7% | N/A | N/A |
#7 | $0.7M | 9 | 29% | N/A | N/A |
#8 | $4M | 20 | -5% | N/A | N/A |
#9 | $1.7M | 11 | 22% | N/A | N/A |
#10 | $7.6M | 49 | 2% | N/A | N/A |
What Is Passage Bio?
Passage Bio was launched with the vision to be a first in class fully-integrated genetic medicines company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 6 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn?s Orphan Disease Center to support these efforts.
keywords:N/A
$379.5M
Total Funding
92
Number of Employees
$25.9M
Revenue (est)
-30%
Employee Growth %
$311.1M
Valuation
N/A
Accelerator
Passage Bio News
PHILADELPHIA, April 22, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on...
Genetic engineering concept. DNA. Gene therapy. Medical technology. metamorworks/iStock via Getty Images. I first became aware of Passage Bio...
Passage Bio has licensed nine options, out of an initial 17 potential ones, for gene therapies which are connected to research out of UPenn's...
October 6, 2021 Download(opens in new window) Philadelphia, PA - October 6, 2021 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced a scholarship program dedicated t ...
PHILADELPHIA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced the closing of a $110.0 million Series B financing. The financing round was ...
Other Companies in Philadelphia
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $29.4M | 92 | 0% | N/A |
#2 | $37.9M | 92 | -14% | N/A |
#3 | $31.1M | 92 | 3% | N/A |
#4 | N/A | 92 | 53% | N/A |
#5 | $27.6M | 93 | 0% | N/A |